The investment firm co-led a $125 million Series A round for Ambros Therapeutics, a Vivek Ramaswamy co-founded company with a ...

The financing follows a strategic shift for Orum, which shelved its original lead program and is now pursuing a potential ...

The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...

The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” ...

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...

The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...

Analysts said the deal makes sense for BioMarin, as it offers a late-stage clinical asset as well as two marketed therapies ...

The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin ...